APA (7th ed.) Citation

LJ, V. E., L, S., K, B., DT, L., RJ, N., B, H., . . . JT, G. (2021). First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. Clinical pharmacology in drug development, 10(2), 131. https://doi.org/10.1002/cpdd.795

Chicago Style (17th ed.) Citation

LJ, Van Eldik, et al. "First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers." Clinical Pharmacology in Drug Development 10, no. 2 (2021): 131. https://doi.org/10.1002/cpdd.795.

MLA (9th ed.) Citation

LJ, Van Eldik, et al. "First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers." Clinical Pharmacology in Drug Development, vol. 10, no. 2, 2021, p. 131, https://doi.org/10.1002/cpdd.795.